Cargando…

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications

The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a significant variability within primary tumors as well...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godoy-Ortiz, Ana, Sanchez-Muñoz, Alfonso, Chica Parrado, Maria Rosario, Álvarez, Martina, Ribelles, Nuria, Rueda Dominguez, Antonio, Alba, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828840/ https://www.ncbi.nlm.nih.gov/pubmed/31737566 http://dx.doi.org/10.3389/fonc.2019.01124

Ejemplares similares

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
por: Chica-Parrado, María Rosario, et al.
Publicado: (2020)

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
por: Díaz-Redondo, Tamara, et al.
Publicado: (2019)

Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management
por: Godoy-Ortiz, Ana, et al.
Publicado: (2022)

The Conundrum of Adjuvant HER2 Treatment Options
por: Bulbul, Ajaz, et al.
Publicado: (2018)

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
por: Sánchez-Muñoz, Alfonso, et al.
Publicado: (2010)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

Deciphering Metabolic Adaptability of Leukemic Stem Cells
por: Patel, Sweta B., et al.
Publicado: (2022)

Editorial: Deciphering the bone marrow microenvironment in hematologic malignancies
por: Wobus, Manja, et al.
Publicado: (2023)

Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index
por: Ribelles, Nuria, et al.
Publicado: (2013)

Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
por: Chow, Christopher Y.C., et al.
Publicado: (2022)

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
por: Yu, Xin, et al.
Publicado: (2022)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Deciphering the Dichotomous Effects of PGC-1α on Tumorigenesis and Metastasis
por: Gravel, Simon-Pierre
Publicado: (2018)

MiRNAs: A Powerful Tool in Deciphering Gynecological Malignancies
por: Duică, Florentina, et al.
Publicado: (2020)

Deciphering immune microenvironment and cell evasion mechanisms in human gliomas
por: Rafii, Soumaya, et al.
Publicado: (2023)

The Biology and Therapeutic Implications of Tumor Dormancy and Reactivation
por: Yadav, Amit S., et al.
Publicado: (2018)

Deciphering the Role of the Coagulation Cascade and Autophagy in Cancer-Related Thrombosis and Metastasis
por: Hill, Charlotte Nicole, et al.
Publicado: (2020)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
por: Tulukcuoglu Guneri, Ezgi, et al.
Publicado: (2022)

Deciphering Pro-Lymphangiogenic Programs during Mammary Involution and Postpartum Breast Cancer
por: Borges, Virginia F., et al.
Publicado: (2016)

Deciphering Epithelial–Mesenchymal Transition Regulatory Networks in Cancer through Computational Approaches
por: Burger, Gerhard A., et al.
Publicado: (2017)

Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities
por: Caprioli, Chiara, et al.
Publicado: (2022)

Deciphering Prognostic Value of TTN and Its Correlation With Immune Infiltration in Lung Adenocarcinoma
por: Chen, Jianing, et al.
Publicado: (2022)

The Potential of panHER Inhibition in Cancer
por: Wang, Xiaochun, et al.
Publicado: (2015)

Corrigendum: Single-cell technologies to decipher the immune microenvironment in myeloid neoplasms: Perspectives and opportunities
por: Caprioli, Chiara, et al.
Publicado: (2022)

GDF11 Implications in Cancer Biology and Metabolism. Facts and Controversies
por: Simoni-Nieves, Arturo, et al.
Publicado: (2019)

A microRNA Signature Associated with Early Recurrence in Breast Cancer
por: Pérez-Rivas, Luis G., et al.
Publicado: (2014)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

Biological and Mechanical Synergies to Deal With Proton Therapy Pitfalls: Minibeams, FLASH, Arcs, and Gantryless Rooms
por: Mazal, Alejandro, et al.
Publicado: (2021)

Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
por: Bontoux, Christophe, et al.
Publicado: (2022)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Deciphering the Role of Regulatory CD4 T Cells in Oral and Oropharyngeal Cancer: A Systematic Review
por: O'Higgins, Caoimhín, et al.
Publicado: (2018)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
por: Yang, Yuqin, et al.
Publicado: (2022)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
por: Garufi, Giovanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ji87mgh80qtsepvcm3qpgfarro